trial

Low Pulse Amplitude Seizure Therapy (LAP-ST Study)

NCTId NCT02928159
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 22 (actual)
Sponsored by Behman Hospital
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-04
Primary completion
2015-06
Eligibility
ALL · 20 Years · 80 Years

Interventions & indications

Drugs
Mecta spectrum 5000Q device

Sponsors

Behman HospitalLead Sponsor

Investigators

2
Nagy A Youssef, MD, PhDPrincipal Investigator
Emad SidhomPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE1
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
Mecta spectrum 5000Q device
drug
lead_sponsor
Behman Hospital
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Nagy A Youssef, MD, PhD
person
Emad Sidhom
person